RecruitingPhase 2NCT07669779

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

A Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of AK146D1 in Combination With AK112 or Other Anticancer Therapies in Patients With Advanced Non-Small Cell Lung Cancer

Sponsor

Akeso

Enrollment

348 participants

Start Date

Jul 10, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Non Small Cell Lung Cancer (NSCLC)

Summary

This is a phase II clinical study evaluating the safety, tolerability, pharmacokinetics and antitumor efficacy of AK146D1 in combination with AK112 or other anticancer therapies in patients with advanced Non-Small Cell Lung Cancer.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AK112 Injection, a drug called AK146D1 for injection, and others for people with advanced non small cell lung cancer (nsclc). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAK146D1 for injection

AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate.

DRUGAK112 Injection

AK112 is a PD-1/VEGF bispecific antibody.

DRUGPlatinum chemotherapy

Carboplatin or cisplatin will be administered.

DRUGOsimertinib

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

Locations(1)

SunYat-sen University Cancer Center

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07669779

Related Trials

AMT-116 in Combination With Ivosidan in Patients With Lung Cancer

NCT075905312 locations

Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway

NCT076496291 location

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

NCT072592261 location

Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors

NCT067735071 location

Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study

NCT067288521 location